Aaron S. Kesselheim, MD, JD, MPH
Harvard Medical School
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital
Aaron S. Kesselheim MD JD MPH is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim).
Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. Aaron is a core faculty member at the HMS Center for Bioethics, where he co-teaches a course on health policy, law, and bioethics and organizes a monthly policy and ethics seminar series. Aaron also serves as the Sidley Austin-Robert D. McLean Visiting Professor of Law at Yale Law School, where he teaches a yearly course on Food and Drug Administration Law and Policy. He recently developed a massive open online course called Prescription Drug Regulation, Cost, and Access: Current Controversies in Context disseminated via the HarvardX platform to over 80,000 participants world-wide (and still available for viewing here: https://www.edx.org/course/the-fda-and-prescription-drugs-current-controversies-in-context). He is the editor-in-chief of the Journal of Law, Medicine, and Ethics and is a member of the Perspectives advisory board for the New England Journal of Medicine. In 2020, he was elected to the National Academy of Medicine.